Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AKRO NYSE:CPSR NASDAQ:CRNX NASDAQ:MRUS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAKROAkero Therapeutics$52.08-4.1%$50.63$21.34▼$58.40$4.15B-0.151.06 million shs881,281 shsCPSRCapstar Special Purpose Acquisition$24.400.0%$8.28$6.06▼$12.23$841.63M0.07556,189 shs291 shsCRNXCrinetics Pharmaceuticals$31.11-5.8%$31.00$24.10▼$62.53$2.91B0.25820,245 shs923,475 shsMRUSMerus$63.26+3.0%$52.47$33.19▼$63.43$4.38B1733,967 shs1.06 million shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAKROAkero Therapeutics0.00%+0.99%-5.14%+38.40%+92.32%CPSRCapstar Special Purpose Acquisition-0.02%+0.18%+1.31%+4.12%+273.58%CRNXCrinetics Pharmaceuticals0.00%-2.57%+2.00%+2.27%-42.23%MRUSMerus0.00%+16.07%+20.29%+46.91%+11.87%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAKROAkero Therapeutics3.6718 of 5 stars3.51.00.04.72.70.80.0CPSRCapstar Special Purpose AcquisitionN/AN/AN/AN/AN/AN/AN/AN/ACRNXCrinetics Pharmaceuticals3.3537 of 5 stars3.40.00.03.71.82.50.0MRUSMerus2.1578 of 5 stars3.61.00.00.02.62.50.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAKROAkero Therapeutics 3.00Buy$82.5058.41% UpsideCPSRCapstar Special Purpose Acquisition 0.00N/AN/AN/ACRNXCrinetics Pharmaceuticals 2.80Moderate Buy$69.50123.40% UpsideMRUSMerus 3.14Buy$84.6433.79% UpsideCurrent Analyst Ratings BreakdownLatest CPSR, AKRO, MRUS, and CRNX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/10/2025CRNXCrinetics PharmaceuticalsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageNeutral$36.006/27/2025CRNXCrinetics PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$81.005/27/2025AKROAkero TherapeuticsBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$63.00 ➝ $64.005/23/2025MRUSMerusBMO Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetOutperform ➝ Outperform$96.00 ➝ $110.005/19/2025MRUSMerusNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$75.00 ➝ $75.005/13/2025AKROAkero TherapeuticsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$80.00 ➝ $78.005/8/2025MRUSMerusWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$91.00 ➝ $89.004/28/2025MRUSMerusWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform(Data available from 7/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAKROAkero TherapeuticsN/AN/AN/AN/A$10.75 per shareN/ACPSRCapstar Special Purpose AcquisitionN/AN/AN/AN/A($1.18) per shareN/ACRNXCrinetics Pharmaceuticals$1.04M2,800.80N/AN/A$14.29 per share2.18MRUSMerus$36.13M121.18N/AN/A$9.46 per share6.69Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAKROAkero Therapeutics-$252.06M-$1.95N/AN/AN/AN/A-15.19%-13.97%8/8/2025 (Estimated)CPSRCapstar Special Purpose Acquisition-$15.30MN/A0.00∞N/AN/AN/AN/AN/ACRNXCrinetics Pharmaceuticals-$298.41M-$3.82N/AN/AN/AN/A-30.95%-28.12%8/7/2025 (Estimated)MRUSMerus-$215.33M-$4.08N/AN/AN/A-506.73%-35.99%-29.83%7/30/2025 (Estimated)Latest CPSR, AKRO, MRUS, and CRNX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/8/2025Q2 2025AKROAkero Therapeutics-$0.95N/AN/AN/AN/AN/A8/7/2025Q2 2025CRNXCrinetics Pharmaceuticals-$1.13N/AN/AN/A$0.52 millionN/A8/7/2025Q1 2025MRUSMerus-$1.17N/AN/AN/AN/AN/A5/14/2025Q1 2025MRUSMerus-$1.17-$1.40-$0.23-$1.40$7.82 million$26.49 million5/12/2025Q1 2025AKROAkero Therapeutics-$1.01$0.90+$1.91$0.90N/AN/A5/8/2025Q1 2025CRNXCrinetics Pharmaceuticals-$0.99-$1.04-$0.05-$1.04$0.10 million$0.36 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAKROAkero TherapeuticsN/AN/AN/AN/AN/ACPSRCapstar Special Purpose AcquisitionN/AN/AN/AN/AN/ACRNXCrinetics PharmaceuticalsN/AN/AN/AN/AN/AMRUSMerusN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAKROAkero Therapeutics0.0316.8016.80CPSRCapstar Special Purpose AcquisitionN/A0.130.13CRNXCrinetics PharmaceuticalsN/A22.5322.53MRUSMerusN/A5.865.86Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAKROAkero TherapeuticsN/ACPSRCapstar Special Purpose Acquisition64.87%CRNXCrinetics Pharmaceuticals98.51%MRUSMerus96.14%Insider OwnershipCompanyInsider OwnershipAKROAkero Therapeutics7.07%CPSRCapstar Special Purpose AcquisitionN/ACRNXCrinetics Pharmaceuticals4.60%MRUSMerus4.57%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAKROAkero Therapeutics3079.72 million74.08 millionOptionableCPSRCapstar Special Purpose Acquisition234.50 millionN/ANot OptionableCRNXCrinetics Pharmaceuticals21093.63 million89.32 millionOptionableMRUSMerus3769.21 million66.05 millionOptionableCPSR, AKRO, MRUS, and CRNX HeadlinesRecent News About These CompaniesInsider Selling: Merus N.V. (NASDAQ:MRUS) COO Sells 25,000 Shares of StockJuly 19 at 6:23 PM | marketbeat.comMerus (NASDAQ:MRUS) Sets New 12-Month High - Here's WhyJuly 19 at 5:01 PM | marketbeat.comAtle Fund Management AB Sells 27,229 Shares of Merus N.V. (NASDAQ:MRUS)July 19 at 9:22 AM | marketbeat.comMerus N.V. (NASDAQ:MRUS) COO Peter B. Silverman Sells 25,000 SharesJuly 19 at 7:04 AM | insidertrades.comMerus (NASDAQ:MRUS) Trading 7.5% Higher - Should You Buy?July 18 at 6:37 PM | marketbeat.comMerus N.V. (NASDAQ:MRUS) Receives Average Recommendation of "Buy" from AnalystsJuly 16, 2025 | americanbankingnews.comMerus N.V. (NASDAQ:MRUS) Given Average Rating of "Buy" by AnalystsJuly 16, 2025 | marketbeat.comMerus N.V. (NASDAQ:MRUS) Shares Sold by CenterBook Partners LPJuly 15, 2025 | marketbeat.comTimesSquare Capital Management LLC Buys 12,510 Shares of Merus N.V. (NASDAQ:MRUS)July 15, 2025 | marketbeat.comCincinnati Children’s, Christ Hospital partner with developer Merus for project in Cold SpringJuly 12, 2025 | nkytribune.comNPeter B. Silverman Sells 6,695 Shares of Merus N.V. (NASDAQ:MRUS) StockJuly 12, 2025 | insidertrades.comMerus (NASDAQ:MRUS) Upgraded by Wall Street Zen to Hold RatingJuly 12, 2025 | marketbeat.comMerus N.V. (NASDAQ:MRUS) COO Sells $368,225.00 in StockJuly 11, 2025 | marketbeat.comMerus N.V. (NASDAQ:MRUS) COO Sells $924,275.00 in StockJuly 11, 2025 | marketbeat.comMRUS Stock Soars 30% in 3 Months After Phase II Cancer Study SuccessJuly 11, 2025 | zacks.comMerus, Bicara Present Promising HNSCC Trial Data at ASCO 2025, Advance Towards Phase IIIJuly 9, 2025 | msn.comKBC Group NV Sells 54,333 Shares of Merus N.V. (NASDAQ:MRUS)July 8, 2025 | marketbeat.comMoody Aldrich Partners LLC Has $4.56 Million Holdings in Merus N.V. (NASDAQ:MRUS)July 4, 2025 | marketbeat.comStocks To Watch: Merus Sees RS Rating Rise To 84July 2, 2025 | msn.comMerus N.V.: Making ProgressJune 29, 2025 | seekingalpha.comMerus N.V. (MRUS) Latest Stock News & Headlines - Yahoo FinanceJune 26, 2025 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCPSR, AKRO, MRUS, and CRNX Company DescriptionsAkero Therapeutics NASDAQ:AKRO$52.08 -2.25 (-4.14%) Closing price 07/18/2025 04:00 PM EasternExtended Trading$52.74 +0.66 (+1.27%) As of 07/18/2025 07:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Akero Therapeutics, Inc., together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients. It has a license agreement with Amgen Inc. to develop, manufacture, use, distribute, and sell EFX as a treatment for MASH and other metabolic diseases. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.Capstar Special Purpose Acquisition NYSE:CPSRCapstar Special Purpose Acquisition Corp. is a blank check company. The company intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities. It intends to focus on businesses in the consumer, healthcare, and technology, media and telecommunications industries. The company was incorporated in 2020 and is based Austin, Texas.Crinetics Pharmaceuticals NASDAQ:CRNX$31.11 -1.91 (-5.78%) Closing price 07/18/2025 04:00 PM EasternExtended Trading$31.46 +0.34 (+1.11%) As of 07/18/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.Merus NASDAQ:MRUS$63.26 +1.82 (+2.96%) Closing price 07/18/2025 04:00 PM EasternExtended Trading$63.24 -0.02 (-0.04%) As of 07/18/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; collaboration with Incyte Corporation for the development of MCLA-145; and collaboration with Gilead Sciences, Inc. to discover novel antibody-based trispecific T-cell engagers. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/14 - 07/18 Netflix Q2 2025 Earnings: What Investors Need to Know High-Flying GE Aerospace Drops After Blowout Q2 — What Now? A New $70 Billion AI Investment Could Push Taiwan Semiconductor Why Prologis May Be the Smartest Backdoor Bet on AI Real Estate Snap-On: Snap Up This Strong Signal While It’s Still Cheap Why Abbott Laboratories Is a Q2 2025 Buy: Growth & Yield Why Pure Storage Is a Core Investment for the AI Era Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
